Tempest Therapeutics (TPST) Research & Development (2012 - 2026)
Tempest Therapeutics (TPST) posted Research & Development of $539000.0 for Q4 2025, down 5.44% sequentially from $570000.0 in Q3 2025, and down 94.98% YoY from $10.7 million in Q4 2024.
Tempest Therapeutics (TPST) Research & Development (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Research & Development for 14 years, with the latest figure at $539000.0 in Q4 2025.
- Quarterly Research & Development fell 94.98% year-over-year to $539000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.6 million (down 55.73% YoY) and the FY2025 annual result came in at $12.6 million, down 55.73% from the prior year.
- Research & Development slipped to $539000.0 in Q4 2025 per TPST's latest filing, from $570000.0 in the prior quarter.
- Over five years, Research & Development peaked at $10.7 million in Q4 2024 and troughed at $539000.0 in Q4 2025.
- A 5-year average of $4.9 million and a median of $4.7 million in 2021 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 156.8% in 2024, then tumbled 94.98% in 2025.
- Over 5 years, Research & Development stood at $4.7 million in 2021, then grew by 22.88% to $5.8 million in 2022, then slipped by 27.8% to $4.2 million in 2023, then surged by 156.8% to $10.7 million in 2024, then sank by 94.98% to $539000.0 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $539000.0, $570000.0, and $3.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | 1.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.82 Mn |
| Dec 31, 2025 | 539,000.00 |
| Sep 30, 2025 | 570,000.00 |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 7.63 Mn |
| Dec 31, 2024 | 10.74 Mn |
| Sep 30, 2024 | 7.56 Mn |
| Jun 30, 2024 | 5.84 Mn |
| Mar 31, 2024 | 4.34 Mn |
| Dec 31, 2023 | 4.18 Mn |
| Sep 30, 2023 | 4.22 Mn |
| Jun 30, 2023 | 4.42 Mn |
| Mar 31, 2023 | 4.68 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Sep 30, 2022 | 5.97 Mn |
| Jun 30, 2022 | 5.65 Mn |
| Mar 31, 2022 | 5.11 Mn |
| Dec 31, 2021 | 4.72 Mn |
| Sep 30, 2021 | 4.63 Mn |
| Jun 30, 2021 | 4.23 Mn |